Singapore markets open in 4 hours 16 minutes

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.8900+0.1557 (+8.98%)
At close: 03:57PM EST
1.8500 -0.04 (-2.12%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.7343
Open1.7000
Bid1.7500 x 3000
Ask1.9000 x 1000
Day's range1.7000 - 1.8900
52-week range1.3600 - 3.4500
Volume30,114
Avg. volume14,273
Market cap9.256M
Beta (5Y monthly)2.02
PE ratio (TTM)N/A
EPS (TTM)-4.8100
Earnings date21 Mar 2024 - 25 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est15.00
  • GlobeNewswire

    Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro

    Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value propositionMore information and materials available at www.AEZSmerger.comShareholders with questions or who require assistance voting their shares should contact Kingsdale Advisors at 1-866-581-1513 (North American Toll Free) or 416-623-2513 (outside North America – text and call enabled) or contactus@kingsdaleadvisors.com TORONTO, Feb. 15, 2024 (GLOB

  • GlobeNewswire

    Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company

    TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, today announced that they have entered into a definitive agreement to combine operations in an all-stock merger of equals transaction (the “Transaction”). The combined company is expected to be listed on the Nasdaq Capital Market (“Nasdaq”) and the Toronto Stock Exchange

  • GlobeNewswire

    Aeterna Zentaris Reports Third Quarter 2023 Financial Results

    - Launch of Ghryvelin™ in a number of key countries in the European Economic Area - Approval of Macrilen® in South Korea in September - Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority pipeline programs into 2025 TORONTO, ONTARIO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmac